# Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD

> **NCT00278200** · PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 23 (actual)

## Conditions studied

- Lymphoproliferative Disorder

## Interventions

- **BIOLOGICAL:** Inactivated EBV-infected vaccine

## Key facts

- **NCT ID:** NCT00278200
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-01
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Loss of funding
- **Last updated:** 2023-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278200, "Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00278200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*